Scarica l'app Stockscreener
43.92
2.86%
1.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Exelixis Inc Borsa (EXEL) Ultime notizie
Why Exelixis Inc. (EX9) stock could be next leader2025 Price Action Summary & Free High Return Stock Watch Alerts - mfd.ru
Illinois Municipal Retirement Fund Boosts Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Aug Wrap: What is the earnings history of Exelixis IncWeekly Earnings Recap & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - Finviz
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
Understanding the Setup: (EXEL) and Scalable Risk - Stock Traders Daily
Assetmark Inc. Has $131.99 Million Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (EXEL) Q4 2025 Earnings Call Transcript - AOL.com
Exelixis stock price target raised to $54 from $52 at H.C. Wainwright - Investing.com Nigeria
Exelixis (EXEL) Receives a Buy from Stephens - The Globe and Mail
RBC Capital Sticks to Its Hold Rating for Exelixis (EXEL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and OrganiGram Holdings (OGI) - The Globe and Mail
Exelixis Reports Solid Earnings-Are New Highs Back on the Table? - Finviz
Exelixis Reports Solid Earnings—Are New Highs Back on the Table? - MarketBeat
Exelixis stock price target raised to $54 from $52 at H.C. Wainwright By Investing.com - Investing.com South Africa
Westover Capital Advisors LLC Grows Stake in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. $EXEL Shares Sold by LSV Asset Management - MarketBeat
EXEL: HC Wainwright & Co. Raises Price Target, Maintains Buy Rat - GuruFocus
A Glimpse Into The Expert Outlook On Exelixis Through 10 Analysts - Benzinga
Can Exelixis Inc. stock outperform in a bear marketInsider Selling & AI Driven Stock Movement Reports - mfd.ru
FDA Review Of Zanzalintinib Combo Highlights Exelixis Valuation Gap - Yahoo Finance
Exelixis (NASDAQ:EXEL) Price Target Raised to $46.00 - MarketBeat
EXEL: Stifel Raises Price Target to $44 and Maintains Hold Ratin - GuruFocus
Exelixis (NASDAQ:EXEL) Price Target Raised to $35.00 - MarketBeat
Citizens maintains Exelixis stock rating on promising cancer treatment data By Investing.com - Investing.com Canada
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus - Yahoo Finance
RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating - marketscreener.com
Citizens maintains Exelixis stock rating on promising cancer treatment data - Investing.com
Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript - Insider Monkey
Essex Investment Management Co. LLC Raises Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements - GuruFocus
Exelixis Inc (EXEL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... - Yahoo Finance
Exelixis Q4 2025 Earnings Call Transcript - MarketBeat
Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch - MSN
Compared to Estimates, Exelixis (EXEL) Q4 Earnings: A Look at Key Metrics - sharewise.com
Exelixis (EXEL) Reports Strong Q4 2025 Earnings with Robust Grow - GuruFocus
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion By Investing.com - Investing.com South Africa
Exelixis Q4 Earnings Call Highlights - Yahoo Finance
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Upda - PharmiWeb.com
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com
Earnings call transcript: Exelixis Q4 2025 reports EPS beat, stock dips - Investing.com India
Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue - ChartMill
Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates - Yahoo Finance
Exelixis: Q4 Earnings Snapshot - KVUE
Why Exelixis (EXEL) is one of the best healthcare stocks under $50 to invest in - MSN
EXEL: Amended Ipsen deal grants exclusive cabozantinib rights outside U.S./Japan, $200M upfront, royalties - TradingView
EXELIXIS, INC. SEC 10-K Report - TradingView
(EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B$2.63B, vs. FactSet Est of $2.62B - marketscreener.com
Exelixis, Inc. Profit Climbs In Q4 - Nasdaq
Exelixis (NASDAQ:EXEL) Posts Quarterly Earnings Results, Beats Expectations By $0.20 EPS - MarketBeat
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update - The Joplin Globe
Exelixis earnings on deck: Can zanzalintinib justify valuation? - Investing.com
Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In - Yahoo! Finance Canada
Stock Report: Will Exelixis Inc outperform its industry peersBreakout Watch & Fast Entry and Exit Trade Plans - baoquankhu1.vn
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):